Welcome to our dedicated page for Nymox Pharm news (Ticker: NYMXF), a resource for investors and traders seeking the latest updates and insights on Nymox Pharm stock.
Nymox Pharmaceutical Corporation is a biopharmaceutical company specializing in drug research and development for the aging population. Their lead drug candidate, Fexapotide Triflutate (NX-1207), has completed Phase III clinical trials for benign prostatic hyperplasia and is in Phase II trials for low-grade localized prostate cancer. The company also markets Nicalert and Tobacalert test strips for tobacco product detection and Alzheimalert, a urine assay for Alzheimer's diagnosis. Founded in 1989 and headquartered in Nassau, Bahamas, Nymox operates globally in Canada, the US, Europe, and beyond.
Nymox Pharmaceutical (NYMXF) has announced the resumption of its stock trading on the OTCQB Venture Market, representing an upgrade from its previous listing tier. This new listing makes the stock eligible for proprietary broker-dealer quotations. The company's president, Paul Averback, expressed gratitude towards the OTC teams for their guidance during the transition process and thanked shareholders and investors for their patience and support. He emphasized the company's focus on advancing prostate treatments to address the market's need for safer and more effective solutions.
Nymox Pharmaceutical (OTC: NYMXF) has announced the filing of its Annual Report with the Securities and Exchange Commission (SEC) on August 29, 2024. The company, which trades on the OTC Markets, made this announcement on August 30, 2024, from Irvine, California. This timely filing of the Annual Report is a important regulatory compliance step for publicly traded companies, providing investors and regulators with essential financial and operational information about the company's performance over the past year.
Nymox Pharmaceutical (OTC: NYMXF) has announced an update on its Annual Report progress. The company began working on the report in late February after receiving previously withheld corporate documents from terminated officers and directors. This situation has led to unexpected delays in completing the report. Despite these challenges, Nymox expects the audit to be finalized soon, with the Annual Report to be issued shortly after. The company acknowledges the delay is beyond its control and is working to release the report as quickly as possible.
Nymox Pharmaceutical (OTC: NYMXF) announced that its Marketing Authorization Application (MAA) to the Danish Medicines Agency (DKMA) for Nymozarfex™ has expired and requires resubmission with a new fee. The current application does not meet the Medicines Act conditions for marketing authorization. Key issues include:
1. Developing an assay method for impurities below 0.1%
2. Providing additional evidence of double-blinding in long-term follow-up studies
3. Addressing remaining questions about data analysis
Nymox believes it has the necessary data for resubmission but cannot guarantee resolution of all issues. The company's MAA to the UK's MHRA is still in process. No significant safety concerns were reported for Nymozarfex in human clinical trials.
FAQ
What is the current stock price of Nymox Pharm (NYMXF)?
What is the market cap of Nymox Pharm (NYMXF)?
What is Nymox Pharmaceutical Corporation known for?
What is the lead drug candidate of Nymox Pharmaceutical Corporation?
What products does Nymox Pharmaceutical Corporation offer?
Where is Nymox Pharmaceutical Corporation headquartered?
When was Nymox Pharmaceutical Corporation founded?
